MYGN
Myriad Genetics, Inc.
MYGN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over MYGN overall, supported by stronger fundamentals and lower modeled downside.
MYGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Under pressure |
MYGN's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MYGN PE Valuation
MYGN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MYGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect MYGN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MYGN on the outlook, with more favorable earnings and revenue expectations.
MYGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$2.96 |
| Q2 2026 | -$1.20 | +$3.08 |
| Q1 2026 | -$4.31 | -$3.19 |
| Q4 2025 | -$3.95 | -$2.54 |
| Q3 2025 | -$4.33 | -$3.05 |
| Q2 2025 | -$4.28 | -$2.49 |
| Q1 2025 | -$1.12 | +$1.68 |
| Q4 2024 | -$1.41 | +$1.77 |
MYGN is still losing money, but far less than before: $1.37 per share over the past year, against $4.33 at its worst in late 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MYGN on earnings quality, reporting a profit while its opponent remains loss making.
MYGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.7M | -1.5% |
| Q2 2026 | $190.7M | -11% |
| Q1 2026 | $200.4M | +2.3% |
| Q4 2025 | $209.8M | -0.4% |
| Q3 2025 | $205.7M | -3.6% |
| Q2 2025 | $213.1M | +0.8% |
| Q1 2025 | $195.9M | -3.1% |
| Q4 2024 | $210.6M | +7.1% |
MYGN's revenue grew through 2023 and has held roughly level since: $203M last quarter, down 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -8.3 points |
| Q2 2026 | -20% | +134 points |
| Q1 2026 | -15% | -0.5 points |
| Q4 2025 | -2.7% | +16 points |
| Q3 2025 | -11% | -1.9 points |
| Q2 2025 | -154% | -137 points |
| Q1 2025 | -15% | -1 points |
| Q4 2024 | -19% | -2.5 points |
MYGN's operating margin was −20% last quarter, down 8.3 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MYGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MYGN on profitability, with a higher operating margin.
MYGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5M | -131% |
| Q2 2026 | -$8.3M | +$5.3M |
| Q1 2026 | -$15.7M | +$600K |
| Q4 2025 | $10.6M | +61% |
| Q3 2025 | $21.1M | +2914% |
| Q2 2025 | -$13.6M | -623% |
| Q1 2025 | -$16.3M | +$2.3M |
| Q4 2024 | $6.6M | +$61.3M |
MYGN has burned cash in most quarters: −$20M over the past year, against −$2M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MYGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +900K shares |
| 1 year | +2.8% | +2.6M shares |
| 3 years | +17% | +13.8M shares |
| 5 years | +17% | +14.2M shares |
| Available history | +29% | +21.3M shares |
MYGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MYGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.3x | Elevated |
MYGN's net debt is about 3.3 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MYGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.3 | Overbought |
MYGN's weekly RSI is 57 (neutral) and its Stochastic is 80 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MYGN PE vs Healthcare Sector
MYGN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MYGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.10 | 11% above |
| 20 week MA | $4.52 | 26% above |
| 50 week MA | $4.88 | 16% above |
| 100 week MA | $6.48 | 12% below |
| 200 week MA | $13.8 | 59% below |
MYGN has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 59% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MYGN on trend strength, trading above more of its moving averages.
MYGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.8 | $18.4 | -31% |
| 2021 | $18.4 | $27.3 | +48% |
| 2022 | $27.3 | $15.6 | -43% |
| 2023 | $15.6 | $19.1 | +22% |
| 2024 | $19.1 | $13.4 | -30% |
| 2025 | $13.4 | $6.48 | -52% |
| 2026 YTD | $6.48 | $5.68 | -12% |
MYGN has finished lower in four of the last six years. It's down 12% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MYGN on returns for 2026, with the stronger performance.